{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:31:29Z","timestamp":1789475489137,"version":"build-2803163510"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Patients with primary aldosteronism (PA) tend to exhibit a high prevalence of osteoporosis (OP) that may vary by whether PA is unilateral or bilateral, and responsive to PA treatment. To explore relationships between bone metabolism, PA subtypes, and treatment outcomes, we performed a systematic review and meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The PubMed, Embase, and Cochrane databases were searched for clinical studies related to PA and bone metabolism markers. Articles that met the criteria were screened and included in the systematic review; the data were extracted after evaluating their quality. R software (ver. 2022-02-16, Intel Mac OS X 11.6.4) was used for the meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 28 articles were subjected to systematic review, of which 18 were included in the meta-analysis. We found that PA patients evidenced a lower serum calcium level (mean difference [MD] = \u20130.06 mmol\/L, 95% confidence interval [CI]: \u22120.10 ~ \u22120.01), a higher urine calcium level (MD = 1.29 mmol\/24\u00a0h, 95% CI: 0.81 ~ 1.78), and a higher serum parathyroid hormone (PTH) level (MD = 2.16 pmol\/L, 95% CI: 1.57 ~ 2.75) than did essential hypertension (EH) subjects. After medical treatment or adrenal surgery, PA patients exhibited a markedly increased serum calcium level (MD = \u20130.08 mmol\/L, 95% CI: \u20130.11 ~ \u20130.05), a decreased urine calcium level (MD = 1.72 mmol\/24\u00a0h, 95% CI: 1.00 ~ 2.44), a decreased serum PTH level (MD = 2.67 pmol\/L, 95% CI: 1.73 ~ 3.62), and an increased serum 25-hydroxyvitamin D (25-OHD) level (MD = \u20136.32 nmol\/L, 95% CI: \u201311.94 ~ \u20130.70). The meta-analysis showed that the ser um PTH level of unilateral PA patients was significantly higher than that of bilateral PA patients (MD = 0.93 pmol\/L, 95% CI: 0.36 ~ 1.49) and the serum 25-OHD lower than that of bilateral PA patients (MD = \u20134.68 nmol\/L, 95% CI: \u20137.58 ~ 1.77). There were, however, no significant differences between PA and EH patients of 25-OHD, or BMD of femoral neck and lumbar spine. BMDs of the femoral neck or lumbar spine did not change significantly after treatment. The meta-analytical results were confirmed <jats:italic>via<\/jats:italic> sensitivity and subgroup analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Excess aldosterone was associated with decreased serum calcium, elevated urinary calcium, and elevated PTH levels; these effects may be enhanced by low serum 25-OHD levels. The risks of OP and fracture might be elevated in PA patients, especially unilateral PA patients, but could be reduced after medical treatment or adrenal surgery. In view, however, of the lack of BMD changes, such hypothesis needs to be tested in further studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1027841","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T06:07:39Z","timestamp":1667196459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Bone and mineral metabolism in patients with primary aldosteronism: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Anning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nrrheum.2014.188","article-title":"Glucocorticoid-induced osteoporosis: who to treat with what agent","volume":"11","author":"Rizzoli","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.574151","article-title":"Primary aldosteronism and bone metabolism: A systematic review and meta-analysis","volume":"11","author":"Shi","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.18.02867-5","article-title":"Bone health among patients with primary aldosteronism: a systematic review and meta-analysis","volume":"44","author":"Loh","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3803\/EnM.2018.33.1.1","article-title":"Bone health in adrenal disorders","volume":"33","author":"Kim","year":"2018","journal-title":"Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105434","article-title":"The crosstalk between aldosterone and calcium metabolism in primary aldosteronism: A possible calcium metabolism-associated aberrant \u2018neoplastic\u2019 steroidogenesis in adrenals","volume":"193","author":"Gao","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MED.0000000000000062","article-title":"Interactions between adrenal-regulatory and calcium-regulatory hormones in human health","volume":"21","author":"Brown","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.09.002","article-title":"Association between aldosterone and parathyroid hormone levels in patients with adrenocortical tumors","volume":"28","author":"Zavatta","year":"2022","journal-title":"Endocr Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00955-2","article-title":"Different roles of the RAAS affect bone metabolism in patients with primary aldosteronism, gitelman syndrome and bartter syndrome","volume":"22","author":"Tang","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20210111-00088","article-title":"Value of serum parathyroid hormone in the diagnosis of primary aldosteronism","volume":"101","author":"Liu","year":"2021","journal-title":"Nat Med J China"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5282-20","article-title":"Primary aldosteronism with parathyroid hormone elevation: A single-center retrospective study","volume":"60","author":"Kometani","year":"2021","journal-title":"Intern Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s42000-021-00319-w","article-title":"Hyperparathyroidism in patients with overt and mild primary aldosteronism","volume":"20","author":"Gravvanis","year":"2021","journal-title":"Hormones (Athens)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14145","article-title":"Unilateral primary aldosteronism as an independent risk factor for vertebral fracture","volume":"92","author":"Yokomoto-Umakoshi","year":"2020","journal-title":"Clin Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-0529-7","article-title":"Abdominal aortic calcification is more severe in unilateral primary aldosteronism patients and is associated with elevated aldosterone and parathyroid hormone levels","volume":"43","author":"Tuersun","year":"2020","journal-title":"Hypertens Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1055\/a-1027-6472","article-title":"Primary and secondary hyperparathyroidism in patients with primary aldosteronism - findings from the German conn\u2019s registry","volume":"128","author":"Asbach","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02348-8","article-title":"Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism","volume":"69","author":"Adolf","year":"2020","journal-title":"Endocrine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00143","article-title":"PTH modulation by aldosterone and angiotensin II is blunted in hyperaldosteronism and rescued by adrenalectomy","volume":"104","author":"Lenzini","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.16.02553-0","article-title":"Improvement of bone turnover markers and bone mineral density following treatment of primary aldosteronism","volume":"43","author":"Loh","year":"2018","journal-title":"Minerva Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2018.33.4.485","article-title":"Effects of altered calcium metabolism on cardiac parameters in primary aldosteronism","volume":"33","author":"Lim","year":"2018","journal-title":"Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-018-0069-7","article-title":"Postmenopausal osteoporosis is associated with elevated aldosterone\/renin ratio","volume":"32","author":"Shu","year":"2018","journal-title":"J Hum Hypertens"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3033","article-title":"Risk of fracture in primary aldosteronism: A population-based cohort study","volume":"32","author":"Wu","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0417","article-title":"Primary aldosteronism as a cause of secondary osteoporosis","volume":"177","author":"Salcuni","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3206","article-title":"Primary aldosteronism as a risk factor for vertebral fracture","volume":"102","author":"Notsu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpv146","article-title":"PTH is a promising auxiliary index for the clinical diagnosis of aldosterone-producing adenoma","volume":"29","author":"Zhang","year":"2016","journal-title":"Am J Hypertens"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12981","article-title":"Factors affecting parathyroid hormone levels in different types of primary aldosteronism","volume":"85","author":"Jiang","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/836529","article-title":"Bone and mineral metabolism in patients with primary aldosteronism","volume":"2014","author":"Petramala","year":"2014","journal-title":"Intl J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2399-1","article-title":"Bone health and aldosterone excess","volume":"24","author":"Ceccoli","year":"2013","journal-title":"Osteoporos Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1660","article-title":"Bone involvement in aldosteronism","volume":"27","author":"Salcuni","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.195891","article-title":"Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma","volume":"60","author":"Rossi","year":"2012","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2183","article-title":"Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study","volume":"97","author":"Pilz","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32834f0451","article-title":"Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism","volume":"30","author":"Maniero","year":"2012","journal-title":"J Hypertens"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/s0895-7061(97)00366-x","article-title":"Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension","volume":"11","author":"Rossi","year":"1998","journal-title":"Am J Hypertens"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(95)00182-O","article-title":"Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas","volume":"8","author":"Rossi","year":"1995","journal-title":"Am J Hypertens"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90328-6","article-title":"Calcium metabolism and parathyroid function in primary aldosteronism","volume":"78","author":"Resnick","year":"1985","journal-title":"Am J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2014.0484","article-title":"The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: a review","volume":"24","author":"Atashi","year":"2015","journal-title":"Stem Cells Dev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070409","article-title":"Inflammatory markers and incident fracture risk in older men and women: the health aging and body composition study","volume":"22","author":"Cauley","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32833d0177","article-title":"Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients","volume":"28","author":"Stehr","year":"2010","journal-title":"J Hypertens"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.03.039","article-title":"Fracture risk in men with congestive heart failure risk reduction with spironolactone","volume":"52","author":"Carbone","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.8.1496","article-title":"Colocalization of glucocorticoid and mineralocorticoid receptors in human bone","volume":"16","author":"Beavan","year":"2001","journal-title":"J Bone Miner Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.333","article-title":"Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations","volume":"26","author":"Gupta","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01910","article-title":"Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone","volume":"63","author":"Brown","year":"2014","journal-title":"Hypertension (dallas tex. : 1979)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14177","article-title":"The effect of vitamin d treatment on clinical and biochemical outcomes of primary aldosteronism","volume":"92","author":"Ismail","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.148619","article-title":"Plasma 25-hydroxyvitamin d and regulation of the renin-angiotensin system in humans","volume":"55","author":"Forman","year":"2010","journal-title":"Hypertension"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2010.05.037","article-title":"Independent association between 1,25-dihydroxyvitamin d, 25-hydroxyvitamin d and the renin-angiotensin system: The ludwigshafen risk and cardiovascular health (LURIC) study","volume":"411","author":"Tomaschitz","year":"2010","journal-title":"Clin Chim Acta"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15219","article-title":"1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1177\/1470320310391922","article-title":"25-hydroxyvitamin d is associated with plasma renin activity and the pressor response to dietary sodium intake in caucasians","volume":"12","author":"Vaidya","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1156","article-title":"Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study","volume":"97","author":"Vaidya","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.122002","article-title":"Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study","volume":"53","author":"Matrozova","year":"2009","journal-title":"Hypertension"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12825","article-title":"Effects of vitamin d supplementation on plasma aldosterone and renin-a randomized placebo-controlled trial","volume":"18","author":"Grubler","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M705495200","article-title":"1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter","volume":"282","author":"Yuan","year":"2007","journal-title":"J Biol Chem"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8821292","article-title":"FGF23: A review of its role in mineral metabolism and renal and cardiovascular disease","volume":"2021","author":"Kurpas","year":"2021","journal-title":"Dis Markers"},{"key":"B52","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2165\/11632200-000000000-00000","article-title":"The phosphatonin FGF23 is associated with the subtle hyperparathyroidism of patients with primary aldosteronism due to an aldosterone-producing adenoma","volume":"19","author":"Ragazzo","year":"2012","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015985","article-title":"Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis","volume":"98","author":"Wu","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.05.016","article-title":"Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice","volume":"78","author":"Harvey","year":"2015","journal-title":"Bone"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3789","article-title":"Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism","volume":"99","author":"Riester","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/11632200-000000000-00000","article-title":"Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma","volume":"19","author":"Rossi","year":"2012","journal-title":"High Blood Press Cardiovasc Prev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1027841\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T06:07:44Z","timestamp":1667196464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1027841\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":56,"alternative-id":["10.3389\/fendo.2022.1027841"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1027841","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"article-number":"1027841"}}